Form 4: OptimizeRx Corp Executive Doug Besch Acquires Restricted Stock Units

Chief Product Officer Doug Besch acquired 4,000 restricted stock units of OptimizeRx Corp on February 15, 2024, which will vest on February 15, 2025.

Summary

• Doug Besch, Chief Product Officer of OptimizeRx Corp, reported a transaction on February 15, 2024.
• Besch acquired 4,000 restricted stock units (RSUs) representing a contingent right to receive shares of OptimizeRx common stock.
• The RSUs will vest in full on February 15, 2025, which is the first anniversary of the grant date.
• Following the reported transaction, Besch beneficially owns 7,848 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of restricted stock units by a key executive is generally a positive sign, indicating confidence in the company's future.

Positives

• The acquisition of restricted stock units by a key executive signals confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units is contingent upon Doug Besch's continued service with the company until February 15, 2025.

Industry Context

Executive compensation through stock grants is a common practice in the tech industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in publicly traded companies, particularly in the technology sector.
• Companies like Veeva Systems and Teladoc Health also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedules and grant sizes are generally determined based on the executive's role, performance, and industry benchmarks.

Stakeholder Impact

• The acquisition of restricted stock units by a key executive can positively influence shareholder confidence.

Key Dates